Clinical Trial Update: Study to Evaluate the Efficacy Safety and Tolerability of QR-421a in Subjects With RP Due to Mutations in Exon 13 of the USH2A Gene With Early to Moderate Vision Loss (Celeste) [Phase 2, Phase 3]

View source ↗

Summary

A Phase 2/3 study evaluating QR-421a for retinitis pigmentosa due to USH2A exon 13 mutations was terminated, with results posted in January 2023.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Retinitis Pigmentosa
• Usher Syndrome Type Ii

Drugs mentioned

• QR-421a

Snippet

Sponsor: Laboratoires Thea | Conditions: Retinitis Pigmentosa, Usher Syndrome Type 2 | Phase 2, Phase 3 | Status: TERMINATED | Results posted: 2023-01-20